Tuesday, May 07, 2002
Front Page |
Southern States |
Other States |
Advts: Classifieds | Employment | Obituary |
By Our Special Correspondent
Dr Mahendranath said the new medicines that had been developed in the past one decade offered new hope and relief to rheumatology patients.
However, the medicines, which had to be imported, were prohibitively expensive in India because of the high import duty (between 50 and 80 per cent) and hence their benefits remained beyond the reach of the poor.
The IRA had made several representations to the Central Government explaining the need to lower the import duty on these medicines. But the response so far had been negative because of the widespread belief that these medicines were not life-saving drugs for which alone such concessions were allowed.
Dr Mahendranath said the IRA would continue its efforts to persuade the Government to lower the levy.
The new treatment facilities and medicines available for rheumatic patients would be the focus of a continuing medical education programme to be held at the Taj Residency tomorrow under the aegis of the Malabar Institute of Medical Sciences (MIMS).
Send this article to Friends by E-Mail
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | Home |
Copyright © 2002, The
Hindu. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of